drugset / Trial / NCT00587496

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

NCT00587496

Phase 1 Unknown 60 enrolled National Eye Institute (NEI)
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether oral Valtrex alone or in combination with aspirin will reduce the shedding of herpes simplex virus DNA in the tears and saliva from volunteers with no evidence of ocular herpes infection. The secretion of virus into the tears and saliva might make people more susceptible to virus infection in the future if their immune system becomes deficient. The study will also try to determine if there is a correlation between shedding of viral DNA and herpes virus antibodies in serum and to determine if subjects are carriers of a special form of a gene in their blood cells, the presence of which may suggest the possibility of an increased susceptability to herpes and to Alzheimer's disease and heart disease.

Timeline

Start
2006-04
Primary completion
2008-07
Completion
2008-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 325 mg Oral
Subject Valacyclovir Unknown 500 mg Oral